NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results ...

During a live event, Karen Seiter, MD, discussed the role of the JAK/STAT pathway in myeloproliferative neoplasms and the use ...

Panelists discuss how managing advanced polycythemia vera requires tailored approaches beyond hydroxyurea when patients show resistance (persistent hematocrit >45%, elevated white blood cell counts, ...

Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives,” published in the ...

Join Drs Tania Jain and Prithviraj Bose as they discuss the available JAK inhibitors and how they use them to treat ...

Today, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Incyte Corp. v. Sun ...

Dermavon, the dermatology arm of China Medical System, filed for a Hong Kong listing with 2024 revenue of RMB 618 million, led by vitiligo drug ruxolitinib and other niche therapies. As it steps out ...

Though not yet approved, investors are already eyeing the drug as a potential blockbuster. Its commercial rights holder in ...

The results offer some of the first glimpses into real-world findings of the Janus kinase inhibitor in patients with ...

Incyte Corporation INCY reported first-quarter 2025 adjusted earnings of $1.16 per share, which beat the Zacks Consensus Estimate of $1.01. The company had recorded adjusted earnings of 58 cents ...

1 Non-GAAP cost of product revenues excludes the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...